Biodesix reported a 42% year-over-year jump in first-quarter 2026 revenue and raised its full-year guidance after diagnostic test volumes and average revenue per test increased. For the three months ended March 31, Biodesix said total revenue reached $25.6 million, beating consensus estimates. The company cited a 37% increase in diagnostic test revenue, alongside a 29% lift in test volumes to 17,800, with average revenue per test improving due to expanded payer coverage and enhancements to revenue cycle management. Development service revenue also more than doubled year over year. Biodesix increased its 2026 total revenue outlook to $108 million to $114 million, projecting about 25% growth at the midpoint. For diagnostics-focused biotech, the update signals demand normalization and payer/channel execution gains that can support both near-term results and ongoing platform commercialization.